Literature DB >> 29531203

Curative lung metastectomy and complete pathological response after neo-adjuvant GEMOX chemotherapy for relapse fibrolamellar hepatocellular carcinoma.

J Y Eng1, S Y Soon2, H Y Winnie Ling3.   

Abstract

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma. It is commonly reported in the younger population with no underlying chronic liver disease and free of viral Hepatitis B and C. Local recurrence and distant metastasis are common despite better prognosis compared to conventional hepatocellular carcinoma. Complete surgical resection is associated with higher median survival and is the mainstay treatment option for localized FL-HCC. Multi-modality therapies such as TACE can be used to downstage upfront unresectable FL-HCC. Complete response with GEMOX chemotherapy has been reported in advanced metastatic FL-HCC and should be considered in upfront unresectable or metastatic disease. We present a case of biopsied proven relapse FL-HCC with oligo- left lung metastasis who successfully underwent a left lung lobectomy after neo-adjuvant GEMOX chemotherapy, and is disease free at 24 months follow up.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29531203

Source DB:  PubMed          Journal:  Med J Malaysia        ISSN: 0300-5283


  1 in total

1.  Trans-arterial therapy for Fibrolamellar carcinoma: A case report and literature review.

Authors:  M M Bernon; K Gandhi; H Allam; S Singh; J Kloppers; E Jonas
Journal:  Int J Surg Case Rep       Date:  2022-03-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.